Final Flashcards
Work only by synergistic spontaneous recovery from NMB
Anticholinesterase (neostigmine/edrophonium)
Anticholinesterase MOA
Inactivate acetyl-cholinesterase in NMJ synaptic cleft
Neostigmine
Dose
Onset
Peak
Duration
0.04-0.07 mg/kg
Onset 1 min
Peak 9 min
Duration 20-30 min
Neostigmine metabolism and excretion
Metabolized in liver
80% excreted in urine in 24 hr
50% excreted unchanged
Muscarinic side effects of anticholinesterases (8)
NV Bradycardia Prolong QT Bronchoconstriction Salivary gland stimulation Miosis Increased GI tone
Ability to maintain head lift requires TOF ratio of
0.6
Ratio of TOF recovery required
0.9
Significant risk to pt recovery with NMB
Residual paralysis
Increase in NMB after a period of recovery
Recurarization
Recurirarization risk increased with
Respiratory acidosis and renal insufficiency
Sugammadex MOA
Encapsulates rocuronium rendering it unavailable to bind at NMJ
Sugammadex is a (chemical makeup)
G-cyclodextrin compound
Gamma cyclodextrin- 8 member sugar ring
Sugammadex is ineffective with
Benzylisoquinoliniums
Mechanism for ions and molecules bonding to metals and other ions
Chelation
Sugammadex properties (4)
Highly water soluble
PH 7.5
Osmolality 300-500mOsmol kg
Molecular wt 2178
Sugammadex metabolism and excretion
Not metabolized and renal excreted unchanged
Sugammadex can bind with drugs other than NMBs
Highest affinity after Roc for
Remifentanil
To re-establish NMB after reversal with sugammadex
Recommend benzylisoquinolinium
Roc will have less profound effect
Sugammadex and coags
limited (<1hr) increase in PTT and PT
Naturally occurring catecholamines
Epi
NE
Dopamine
Synthetic catecholamines
Isoproterenol
Dobutamine
Synthetic non-catecholamines
Ephedrine
Amphetamines
Phenylephrine
Methoxamine
Mephentermine
Alpha 1 couples to a Gq resulting in
Increased intracellular Calcium
Alpha 2 couples to Gi results in
Decreased cAMP activity